Omnicell (NASDAQ:OMCL) Posts Quarterly Earnings Results, Beats Expectations By $0.16 EPS

Omnicell (NASDAQ:OMCL) announced its quarterly earnings results on Thursday. The company reported $0.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.42 by $0.16, Briefing.com reports. Omnicell had a return on equity of 5.66% and a net margin of 3.13%. During the same period in the prior year, the business posted $0.51 EPS. The company’s revenue for the quarter was down .9% on a year-over-year basis.

Here are the key takeaways from Omnicell’s conference call:

• Third-quarter results exceeded guidance, with revenue of $308 million and non-GAAP EBITDA of $45 million, supported by favorable product mix, gross margins, disciplined spending, and cost efficiencies.
• Omnicell raised full-year 2026 non-GAAP EBITDA guidance to $187 million–$193 million and EPS guidance to $2.48–$2.56, while narrowing revenue and ARR ranges because of improved visibility.
• The company said the Titan XT and OmniSphere pipeline grew modestly and became more mature, with Titan XT shipments beginning shortly and OmniSphere general availability still targeted for the first half of 2027. Management views OmniSphere subscriptions as a potentially high-margin, incremental revenue stream over time.
• Product bookings remain heavily back-end weighted, and management cited the timing of medium and large health-system decisions, competitive deal outcomes, and lengthy implementation cycles as sources of quarter-to-quarter variability.
• Second-half memory and component costs are expected to reduce margins by roughly $6 million, with about half incurred in the third quarter and the remainder expected in the fourth quarter; policy changes surrounding the 340B program are also expected to have a modest impact on 2026 ARR.

Omnicell Price Performance

Omnicell stock traded down $0.02 during trading hours on Thursday, hitting $35.93. 430,889 shares of the company traded hands, compared to its average volume of 639,864. The firm has a market cap of $1.63 billion, a P/E ratio of 43.04, a P/E/G ratio of 0.95 and a beta of 0.98. The company has a quick ratio of 1.43, a current ratio of 1.64 and a debt-to-equity ratio of 0.13. The firm’s 50-day simple moving average is $34.57 and its two-hundred day simple moving average is $39.26. Omnicell has a 1-year low of $30.69 and a 1-year high of $55.00.

Analysts Set New Price Targets

Several brokerages have weighed in on OMCL. Wells Fargo & Company dropped their target price on Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. Zacks Research upgraded shares of Omnicell from a “strong sell” rating to a “hold” rating in a research report on Monday, September 7th. Piper Sandler reaffirmed an “overweight” rating and issued a $45.00 price objective (down from $55.00) on shares of Omnicell in a report on Monday, August 3rd. Weiss Ratings upgraded shares of Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 18th. Finally, KeyCorp reiterated an “overweight” rating on shares of Omnicell in a research report on Monday, August 24th. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, Omnicell presently has an average rating of “Moderate Buy” and a consensus price target of $57.86.

About Omnicell

Omnicell, Inc develops medication management and adherence solutions for health care providers, pharmacies and patients. Its technologies are designed to help automate medication dispensing, improve inventory control, support clinical workflows and enhance medication access and adherence across the care continuum.

The company’s product portfolio includes automated dispensing cabinets for hospitals and health systems, central pharmacy and intravenous compounding automation, medication packaging and adherence solutions, and software for analytics, inventory management and pharmacy operations.